IRIS
MOSCARELLA, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.968
AS - Asia 1.703
NA - Nord America 1.379
SA - Sud America 362
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 5.444
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.348
RU - Federazione Russa 952
SG - Singapore 596
CN - Cina 453
IE - Irlanda 409
BR - Brasile 303
HK - Hong Kong 301
IT - Italia 141
DE - Germania 135
VN - Vietnam 129
GB - Regno Unito 128
KR - Corea 89
IN - India 51
GR - Grecia 47
SE - Svezia 33
AR - Argentina 30
UA - Ucraina 28
MX - Messico 21
AT - Austria 19
TR - Turchia 19
FI - Finlandia 18
FR - Francia 17
BD - Bangladesh 16
BE - Belgio 14
ID - Indonesia 14
EC - Ecuador 9
ZA - Sudafrica 9
CO - Colombia 7
MA - Marocco 7
CA - Canada 6
ES - Italia 6
IQ - Iraq 6
JP - Giappone 6
NL - Olanda 6
PK - Pakistan 5
VE - Venezuela 5
EG - Egitto 4
KE - Kenya 4
CL - Cile 3
IL - Israele 3
LT - Lituania 3
PL - Polonia 3
AM - Armenia 2
DK - Danimarca 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
NP - Nepal 2
SA - Arabia Saudita 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
MU - Mauritius 1
NG - Nigeria 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 5.444
Salva come PNG Salva come JPEG
Città #
Dublin 403
Moscow 309
Hong Kong 301
Santa Clara 297
Singapore 233
Chandler 212
New York 138
Seoul 89
Hefei 84
Bremen 60
Princeton 58
Roxbury 56
Beijing 51
Ho Chi Minh City 49
The Dalles 47
Medford 43
Jacksonville 42
Ashburn 35
Boardman 30
Bengaluru 29
Naples 28
Des Moines 24
Dallas 23
São Paulo 23
Hanoi 21
Nuremberg 21
Falkenstein 18
Los Angeles 18
Rio de Janeiro 17
Cambridge 15
Wilmington 15
Brussels 14
Jinan 14
Nanjing 14
Hyderabad 11
Caserta 10
Ann Arbor 9
Helsinki 9
Munich 9
Aversa 8
Belo Horizonte 8
Brasília 8
Guangzhou 8
Sivas 8
Vienna 8
Zhengzhou 8
Hangzhou 7
Mexico City 7
Shenyang 7
Stockholm 7
Hebei 6
Johannesburg 6
Rome 6
Boston 5
Changsha 5
Columbus 5
Curitiba 5
Ercolano 5
Guayaquil 5
Haiphong 5
Houston 5
Joinville 5
Tianjin 5
Woodbridge 5
Campinas 4
Da Nang 4
Dhaka 4
Lappeenranta 4
London 4
Malang 4
Milan 4
Nairobi 4
Ninh Bình 4
Shanghai 4
Bari 3
Bogotá 3
Bologna 3
Boone 3
Carapicuíba 3
Casablanca 3
Casier 3
Chennai 3
Columbia 3
Düsseldorf 3
Frankfurt am Main 3
Goiânia 3
Haikou 3
Istanbul 3
Itaquaquecetuba 3
Lanzhou 3
Marano Di Napoli 3
Ningbo 3
Paris 3
Phủ Lý 3
Praia Grande 3
Qingyuan 3
Santiago 3
Serra 3
Taiyuan 3
Taizhou 3
Totale 3.154
Salva come PNG Salva come JPEG
Nome #
Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. 107
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 106
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 105
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study) 101
Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy 101
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 100
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 97
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 96
null 93
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 91
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 91
Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry) 89
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 89
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. 85
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 84
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study 84
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 79
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management 79
Bioresorbable Vascular Scaffolds in In-Stent Restenosis 78
Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry 78
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 75
One-Year Clinical Outcomes After Unrestricted Implantation of Absorb Bioresorbable Scaffold (RAI Registry) 74
Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry 74
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 73
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 73
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 71
Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? 71
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 71
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 71
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 70
Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry) 70
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 68
One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry 67
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 65
Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis 64
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 62
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 61
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 61
Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry 61
Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial 59
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry 58
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 58
Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies 58
IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry 58
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 57
Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry 57
Latest STEMI treatment: a focus on current and upcoming devices 56
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial 56
Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy 55
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 55
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 55
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 55
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 54
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 54
Methods to assess bioresorbable vascular scaffold devices behaviour after implantation 54
Multi-step percutaneous treatment of post-myocardial infarction ventricular septal defects: A case report and review of literature 54
Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis 53
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial) 53
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 52
Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology 51
Alternative Approaches for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: The Call for a Personalized Treatment 50
How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection? 50
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation 50
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 49
Sex-Related Differences in Long-Term Outcomes After Early-Onset Myocardial Infarction 49
New percutaneous interventions in heart failure 49
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 48
QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial 47
Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA) 46
Severely calcified coronary artery lesions: focus on interventional management 46
Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre registro absorb italiano (RAI registry) 46
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 45
First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis 45
Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis 45
In-stent restenosis because of nickel hypersensitivity: A bioresorbable solution? 45
Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention 44
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 44
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 44
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 44
Letter regarding "hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI" 42
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience 41
Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes 41
Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term 40
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 39
Time for implementing high-sensitivity cardiac troponin assays in emergency departments in Italy 39
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) 38
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up 36
Five-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT 35
Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium 35
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 26
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 20
Totale 5.615
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 0 37 2 2 7 48 6
2021/2022385 5 0 0 17 121 9 5 31 8 27 28 134
2022/2023777 93 58 12 50 108 35 3 34 356 1 11 16
2023/2024465 20 8 9 11 99 137 27 0 3 17 21 113
2024/20251.293 2 21 5 49 194 156 190 122 165 199 118 72
2025/20262.344 215 282 334 329 486 698 0 0 0 0 0 0
Totale 5.615